Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,033.74
(
0.15%
)
US TECH 100
25,585.20
(
0.35%
)
Dow Jones
48,553.52
(
0.04%
)
Brent Oil
95.42
(
2.97%
)
Bitcoin
74,854.18
(
0.04%
)
News Focus
News Focus
Post# of 257416
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122871
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 243107

Friday, 12/23/2022 6:49:05 PM

Friday, December 23, 2022 6:49:05 PM

Post# of 257416
AMTI—(-58%)—fails another phase-2 in UC:

https://finance.yahoo.com/news/applied-molecular-transport-announces-top-223000851.html

Similar clinical remission rates observed in patients receiving AMT-101 monotherapy compared to placebo at week 12

The prior phase-2 failure was in a trial testing AMT-101 as an addend to Humira (#msg-169325900). The failure reported today was in a trial testing AMT-101 vs placebo. Moral: AMT-101 does not have activity against UC.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today